Streetbeat News

ENVB

Enveric Biosciences, Inc.

https://www.enveric.com

Industry

Biotechnology

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Open

1.69

Mkt cap

3.3M

Volume

79K

High

1.78

P/E Ratio

-0.05

52-wk high

420.75

Low

1.64

Div yield

N/A

52-wk low

1.13

Several mergers and acquisitions have been announced in the psychedelics sector. Cybin (NYSE:CYBN) is acquiring Small Pharma (OTC:DMTTF), Silo Wellness (OTC:SILFF) is buying NUGL Inc./Kaya Group (OTC:NUGL), and Mindset Pharma (OTC:MSSTF) is being acquired by Otsuka America Inc., part of Otsuka Holdings (OTC:OTSKF). Additionally, Psyched Wellness (OTC:PSYCF) is set to receive $7.5M in financing. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has seen a slight increase in its share price.

Portfolio Pulse from Lara Goldstein

September 05, 2023 | 2:08 pm

Enveric Biosciences (NASDAQ:ENVB) has been granted a new U.S. patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives, which includes EB-373, a new chemical entity psilocin prodrug. The patent provides Enveric with intellectual property rights for compositions and methods for tryptamine-derived prodrugs. This strengthens Enveric's intellectual property portfolio and distinguishes its tryptamine-based prodrugs from similar compounds being developed for the treatment of mental health disorders.

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:03 pm

A recent study published in the Journal of the American Medical Association suggests that a single dose of psilocybin, a psychedelic compound produced by certain types of mushrooms, may have lasting benefits for people with major depressive disorder. The study adds to the growing body of evidence supporting the potential efficacy of psilocybin for depression treatment.

Portfolio Pulse from Happy Mohamed

August 31, 2023 | 3:08 pm

During Tuesday's pre-market session, several health care stocks experienced significant movement. Axcella Health, Tivic Health Systems, Celularity, Shuttle Pharmaceuticals, Comera Life Sciences, and Bionomics saw increases in their share prices, with Axcella Health leading with a 222.2% increase. On the other hand, T2 Biosystems, YS Biopharma, Myomo, Enveric Biosciences, NeuroPace, and Novo Integrated Sciences experienced declines, with T2 Biosystems leading the decline with a 10.7% decrease.

Portfolio Pulse from Benzinga Insights

August 29, 2023 | 1:06 pm

Enveric Biosciences (NASDAQ:ENVB) has been granted a US patent for its lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder. The patent covers compositions and methods for tryptamine-derived prodrugs. The company believes these enhancements could provide a more rapid onset of action and reduced side effects compared to traditional psilocin prodrugs. Enveric is also advancing EVM201 and EVM301 series towards creating innovative alterations to related compounds for treating critical mental health disorders.

Portfolio Pulse from Lara Goldstein

August 28, 2023 | 8:08 pm

Several studies and trials are set to assess the use of psilocybin-assisted therapy for various addictions and pain management. Former NHL player Kyle Quincey is building a psilocybin-assisted therapy center in Colorado. GH Research, Cybin, Enveric Biosciences, Red Light Holland, Incannex Healthcare, and Sunstone Therapies have made significant advancements in their respective programs. The AdvisorShares Psychedelics ETF has seen a consistent lowering trend in its price. GH Research, COMPASS Pathways, Mind Medicine, Bright Minds Biosciences, Enveric Biosciences, Silo Pharma, atai Life Sciences, Incannex Healthcare, FSD Pharma, and Seelos Therapeutics saw varied closing prices.

Portfolio Pulse from Lara Goldstein

August 28, 2023 | 8:07 pm

Enveric Biosciences has been granted Patent No. 11,707,441 by the U.S. Patent and Trademark Office. The patent covers EB-373, a new chemical entity psilocin prodrug being developed by Enveric for the treatment of anxiety disorder.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:05 pm

The article lists the cannabis stocks that gained and lost on August 24, 2023. Notable gainers include EVIO, Red White & Bloom Brands, and CBD Unlimited. Major losers include Choom Holdings, Radient Technologies, and Target Group.

Portfolio Pulse from Benzinga Insights

August 24, 2023 | 9:30 pm

On August 23, 2023, several marijuana stocks experienced significant price movements. Notable gainers included Hemp (OTC:HEMP), 1933 Industries (OTC:TGIFF), and SLANG Worldwide (OTC:SLGWF), while notable losers included Red White & Bloom Brands (OTC:RWBYF), Heritage Cannabis Holding (OTC:HERTF), and CordovaCann (OTC:LVRLF).

Portfolio Pulse from Benzinga Insights

August 23, 2023 | 9:30 pm

The article lists the marijuana stocks that gained and lost on August 22, 2023. The biggest gainers were Red White & Bloom Brands (OTC:RWBYF), Radient Technologies (OTC:RDDTF), and Heritage Cannabis Holding (OTC:HERTF). The biggest losers were EVIO (OTC:EVIO), Choom Holdings (OTC:CHOOF), and Tetra Bio Pharma (OTC:TBPMF).

Portfolio Pulse from Benzinga Insights

August 22, 2023 | 9:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.